International journal of cancer
August 18, 2026 · via Europe PMC
Genomic and Transcriptomic Analysis of Sinonasal Mucosal Melanoma and Conjunctival Melanoma.
Cui J, Zhao X, Zhang H, Ma D, Li R, Piao Y.
AI summary — for doctors, generated from the abstract only
Sinonasal and conjunctival melanomas share RTK-RAS pathway disruption, and RAS mutations in sinonasal tumors tracked with shorter progression-free survival.
What was studied
Whole-exome and RNA sequencing of 25 sinonasal mucosal melanomas and 9 conjunctival melanomas, compared head to head.
Key findings
- NRAS mutations occurred in 20% of sinonasal and 22% of conjunctival cases; RAS mutations predicted shorter progression-free survival in sinonasal disease.
- Conjunctival melanomas had more UV-associated mutations; two novel gene fusions (PTPRK::PAX3, GNA13::NF1) appeared in sinonasal tumors.
- Nearly all tumors had RTK-RAS pathway alterations, and sinonasal tumors had more cancer-associated fibroblasts but fewer CD4+ T cells.
Clinical relevance
Non-cutaneous melanomas are rare and poorly guided by cutaneous data, so their molecular profile can inform testing and trial selection for head and neck and ophthalmic oncologists.
Who should care
Limitations
Very small sample sizes from presumably limited centers, so frequencies and survival associations are imprecise.
Consider comprehensive molecular profiling for mucosal and conjunctival melanoma, recognizing that RAS status may carry prognostic information in sinonasal disease.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
This study compared 25 sinonasal mucosal melanomas (SNMM) and 9 conjunctival melanomas (CM) using whole-exome and RNA sequencing. Median patient age was 64 years for SNMM and 54 years for CM. SNMM predominantly occurred in the nasal cavity (14/25, 56%) or both nasal cavity and paranasal sinuses (9/25, 36%). All CM cases were unilateral. NRAS mutations were found in 20% (5/25) of SNMM and 22% (2/9) of CM cases. RAS mutations were significantly associated with shorter progression-free survival in SNMM. BRAF mutations were detected in 22% (2/9) of CM cases (all V600E) and 8% (2/25) of SNMM cases (non-V600E). NF1 mutations occurred in 16% (4/25) of SNMM and 11% (1/9) of CM cases. Only one KIT mutation was found, in an SNMM case. Nearly all SNMM and CM cases exhibited alterations in the RTK-RAS signaling pathway. CM showed a higher frequency of UV-associated mutations than SNMM. RNA sequencing identified two novel gene fusions (PTPRK::PAX3 and GNA13::NF1) in SNMM. The most common tumor microenvironment subtype in both was D-type. SNMM had higher cancer-associated fibroblast infiltration but lower CD4+ T cell infiltration than CM. Among tumor suppressor genes, CDKN2B exhibited the highest frequency of biallelic inactivation in SNMM (5/25, 20%) and CM (1/6, 17%). Reactome pathway enrichment analysis revealed enrichment of cell cycle-related pathways in both tumor types. In conclusion, these findings delineate distinct genomic profiles of SNMM and CM, revealing significant pathogenic similarities, particularly the involvement of the RTK-RAS pathway and cell cycle-related pathways, despite potential differences in etiological factors.
DOI
10.1002/ijc.70671
PMID
42613908
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed